Positive Seizure Control in Children with DEND Syndrome
⚠️ Infant dosing/safety: medication and diet decisions for infants require individualized medical guidance.
Source: Annals of Indian Academy of Neurology
Summary
Researchers studied three children diagnosed with DEND syndrome, which includes developmental delay, epilepsy, and neonatal diabetes. This syndrome is caused by specific genetic mutations. The children were switched from insulin to a medication called sulfonylurea shortly after their diagnosis to see how it would affect their seizures and overall development over time.
The key findings showed that all three children experienced good control of their seizures after starting sulfonylurea. However, they still faced some challenges with their development, meaning they had varying levels of difficulties in learning and other skills. This suggests that while the medication helped with seizures, it did not completely resolve the developmental issues.
This study is important because it highlights the potential benefits of sulfonylurea for managing seizures in children with DEND syndrome. However, the small number of children studied means that more research is needed to understand how effective this treatment is for a larger group. This will help doctors make better decisions for children with this rare condition in the future.
Free: Seizure First Aid Quick Guide (PDF)
Plus one plain-language weekly digest of new epilepsy research.
Unsubscribe anytime. No medical advice.
